TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06978660: Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis

Sponsor: Idoven 1903 S.L. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 2200 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT06978660 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06978660 Rescue Dossier →